Diffuse large B-cell lymphoma (DLBCL) patients have gene features that modulate their prognosis and response to R-CHOP therapy, according to a study published in Tumour Biology.
Single nucleotide variants (SNVs) in vascular endothelial growth factor A (VEGFA) and VEGFA receptor (KDR) genes display varying inherited abilities in angiogenesis (AG) pathway.
The researchers wrote that the aim of this study was to “evaluate influence of six VEGFA and four KDR SNVs in clinical features and survival of diffuse large B-cell lymphoma (DLBCL) patients.”
In this study, the team assessed 168 DLBCL patients diagnosed between June 2009-September 2014. All patients were homogeneously treated with R-CHOP. Genotypes were identified in genomic DNA by real-time polymerase chain reaction.
Following analysis, the results demonstrated that VEGFA -634CC and +936CT or TT genotypes were at increased risk of showing grade III / IV toxicities and failure to achieving complete remission with treatment. Moreover, the results showed that shorter event-free and overall survival in patients with VEGFA -1154GA or AA genotype and VEGFA ATAGCC haplotype.
“Our data suggest that inherited abnormalities in AG’s gene modulate clinical features and prognosis of DLBCL patients homogeneously treated with R-CHOP,” the authors concluded.